Biomanufacturing Excellence Act of 2025

# Biomanufacturing Excellence Act of 2025 - Summary **What the Bill Would Do:** The Biomanufacturing Excellence Act of 2025 is designed to strengthen the United States' ability to manufacture biological products and medicines domestically. While specific provisions aren't detailed in available records, bills with this title typically aim to support the development and production of biopharmaceuticals, vaccines, and other biotech products made in American facilities rather than relying on foreign manufacturing. **Who It Affects:** This legislation would impact biotech companies, pharmaceutical manufacturers, healthcare workers, patients relying on biologics and vaccines, and workers in the manufacturing sector. It could also affect federal agencies involved in regulating and supporting biotech industries. **Current Status:** As of now, the bill (S 3188) is in committee, meaning it has been introduced but hasn't yet been debated or voted on by the full Senate.

It was introduced by Senator Christopher Coons (D-Delaware). Without the specific legislative text available, the exact provisions—such as funding amounts, tax incentives, or regulatory changes—cannot be detailed.